Genetics and the clinical approach to paragangliomas
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
This study analyses new information on gene mutations in paragangliomas and puts them into a clinical context. A suspicion of malignancy is critical to determine the workup and surgical approach in adrenal (A-PGL) and extra-adrenal (E-PGL) paragangliomas (PGLs). Malignancy rates vary with location, family history, and gene tests results. Currently there is no algorithm incorporating the above information for clinical use. A sum of 1-821 articles were retrieved from PubMed using the search terms paraganglioma genetics. Thirty-seven articles were selected of which 9 were analyzed. It was found that 599/2-487 (24%) patients affected with paragangliomas had a germline mutation. Of these 30.2% were mutations in SDHB, 25% VHL, 19.4% RET, 18.4% SDHD, 5.0% NF1, and 2.0% SDHC genes. A family history was positive in 18.1-64.3% of patients. Adrenal PGLs accounted for 55.1% in mutation (+) and 81.0% in mutation (-) patients (RR 1.2, p<0.0001). Bilateral A-PGLs accounted for 56.4% in mutation (+) and 3.2% in mutation (-) patients (RR 8.7, p<0.0001). E-PGL were found in 33.6% of mut+ and 17.3% of mut- (RR 1.7, p<0.0001). In mutation (+) patients PGLs malignancy varied with location, adrenal (6.4%) thoraco-abdominal E-PGL (38%), H & N E-PGL (10%). Malignancy rates were 8.2% in mutation (-) and lower in mutation (+) PGLs except for SDHB 36.5% and SDHC 8.3%. Exclusion of a mutation lowered the probability of malignancy significantly in E-PGL (RR 0.03 (95% CI 0.1-0.6); p<0.001). Mutation analysis provides valuable preoperative information to assess the risk of malignancy in A-PG and E-PGLs and should be considered in the work up of all E-PGL lesions.
Details
Original language | English |
---|---|
Pages (from-to) | 964-973 |
Number of pages | 10 |
Journal | Hormone and metabolic research |
Volume | 46 |
Issue number | 13 |
Publication status | Published - Dec 2014 |
Peer-reviewed | Yes |
External IDs
PubMed | 25014332 |
---|
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- cancer, germline mutations, malignancy, paraganglioma